CHD1L and non-small cell lung carcinoma: Excitingly, after cisplatin treatment the cells with endogenous levels of CHD1L became the dominant population (Supplementary Fig. 1c), indicating that CHD1L contributes to cisplatin resistance and suppression of cisplatin-induced apoptosis in NSCLC cells.